Visura: Bericht - SECA
Visura: Bericht - SECA
Visura: Bericht - SECA
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
M&A-Bulletin<br />
Juni 2009<br />
Pharmaceuticals<br />
Buyside / Investment<br />
Region Asia, Singapore<br />
Titel Anti-Cancer Herbal Oral Supplement<br />
Firmenangebote – Verkauf – Nachfolge<br />
Rest der Welt<br />
Short description The company is seeking to raise an equity investment of USD 6 million in exchange<br />
for a 10% equity stake. The funds raised will be mainly used to commercialize an<br />
anti-cancer herbal oral supplement. It is an herbal oral supplement that treats different<br />
types of cancers including patients who have developed resistance to their<br />
current cancer drugs. It can be sold over-the-counter without prescription. An advantage<br />
that this drug has is the absence of toxic side-effects that will result from<br />
chemotherapy and medical treatments. All components of the supplement are natural<br />
and do not contain yeast, artificial coloring and flavor. It also does not contain<br />
any prescription drugs or steroids.<br />
Turnovercategory<br />
# Employees<br />
(heads)<br />
Pricecategory<br />
-<br />
-<br />
EUR 2 to 5 Mio.<br />
Engagement just financial<br />
engagement<br />
Reference „Pharma Ant-Cancer 09“<br />
Contact Jan Weidlich<br />
+65 6828 9118 ext. 822<br />
janweidlich@bdo.com.sg<br />
just<br />
management<br />
both<br />
Seite 57 / 109
Change language